Sinobioway Medicine(SZ:002581) 21世纪经济报道·2025-04-24 14:56Core Viewpoint - Unimed Pharmaceutical's subsidiary, Tianjin Unimed Biopharmaceutical Co., has been suspended from production and sales due to non-compliance with GMP standards, which may significantly impact the company's operations and could lead to further risk warnings if production does not resume within three months [1][6]. Financial Performance - In 2024, Tianjin Unimed generated revenue of 217 million yuan and a net profit of -14.0037 million yuan, accounting for 60.09% of Unimed's total revenue and 9.8% of its consolidated net profit [4]. - Unimed's 2024 annual report indicated a total revenue of 360 million yuan, a year-on-year decrease of 16.14%, and a net loss of 137 million yuan, with losses widening by 58.70% compared to the previous year [8]. Regulatory Actions - The suspension was initiated following a GMP compliance inspection by the Tianjin Municipal Drug Administration, which found that Tianjin Unimed's production practices did not meet the required standards [5][6]. - In response, Unimed has established a special rectification team to identify issues and develop a corrective action plan while cooperating with regulatory authorities to address deficiencies [7]. Market Reaction - Following the announcement, Unimed's stock price fell by 2.49%, closing at 8.24 yuan per share, with a total market capitalization of 5.436 billion yuan [9].